canin
parvoviru
cpv
genu
protoparvoviru
member
famili
parvovirida
subfamili
parvovirina
small
highli
contagi
nonenvelop
singlestrand
dna
viru
cpv
major
caus
agent
acut
gastroenter
leukopenia
myocard
dog
typic
clinic
sign
includ
vomit
fever
diarrhea
gener
puppi
age
week
month
found
suscept
cpv
infect
cpv
genom
approxim
kb
length
contain
two
open
read
frame
orf
encod
nonstructur
protein
two
structur
protein
emerg
late
variant
report
sever
countri
distribut
among
five
contin
hoelzer
et
al
shackelton
et
al
previous
report
cpv
genom
substitut
rate
similar
rna
virus
earliest
type
replac
three
main
year
despit
widespread
use
inactiv
live
attenu
vaccin
emerg
antigen
variant
influenc
matern
antibodi
contribut
question
efficaci
commerci
vaccin
addit
suitabl
antivir
drug
avail
specif
treatment
cpv
infect
therefor
treatment
option
infect
support
symptombas
care
thu
import
obtain
antivir
drug
potenti
therapeut
use
canin
parvovir
diarrhea
drug
repurpos
screen
especi
screen
exist
drug
view
altern
effici
method
speed
drug
develop
therefor
food
drug
administr
fda
approv
drug
librari
recent
wide
use
success
screen
inhibitor
dna
rna
virus
includ
ebola
ebov
zika
zikv
hepat
b
hbv
virus
studi
highthroughput
screen
assay
base
cytopath
effect
cpe
use
screen
fdaapprov
drug
librari
potenti
drug
capabl
inhibit
cpv
infect
one
new
variant
first
use
prototyp
screen
librari
two
new
new
use
evalu
broadspectrum
antivir
activ
identifi
drug
three
identifi
inhibitor
promis
drug
candid
cpv
infect
felin
kidney
fibroblastlik
monolay
cell
line
origin
obtain
american
type
cultur
collect
atcc
cell
cultur
growth
medium
gm
consist
dulbecco
modifi
eagl
medium
dmem
gibco
grand
island
ny
usa
supplement
heatinactiv
fetal
calf
serum
uml
penicillin
streptomycin
mainten
medium
mm
consist
dmem
gibco
supplement
heatinactiv
fetal
calf
serum
use
new
strain
new
strain
new
strain
isol
identifi
laboratori
sequenc
encod
protein
deposit
genbank
access
number
respect
submit
sequenc
share
high
nucleotid
sequenc
ident
new
new
new
respect
fdaapprov
librari
purchas
selleck
chemic
usa
consist
drug
prior
use
mm
drug
transfer
mainten
medium
new
plate
prepar
stock
solut
firstli
cell
cellswel
pretreat
stock
solut
obtain
final
concentr
h
drugtreat
cell
infect
cpv
multipl
infect
moi
normal
cpv
cell
contain
final
concentr
dmso
use
posit
neg
control
respect
cell
viabil
examin
cell
count
kit
transgen
biotech
beij
china
h
postinfect
optic
densiti
od
nm
wavelength
collect
use
synergi
micropl
reader
biotek
instrument
inc
winooski
vt
usa
valu
well
without
cpv
infect
serv
posit
cell
control
indic
cpe
inhibit
valu
well
infect
serv
neg
viru
control
indic
cpe
inhibit
percentag
inhibit
calcul
use
formula
percentag
cpe
inhibit
drug
treat
cell
neg
control
posit
control
neg
control
drug
plate
setup
duplic
primari
screen
drug
show
greater
cpe
inhibit
primari
screen
use
second
round
screen
valid
identifi
drug
conduct
triplic
drug
show
greater
cpe
inhibit
use
analysi
dose
respons
experi
perform
test
drug
describ
minor
modif
assay
cell
cellswel
mix
predilut
drug
final
concentr
rang
assay
cell
cellswel
pretreat
predilut
drug
final
concentr
rang
h
treat
cell
infect
cpv
moi
assay
done
triplic
cell
cytotox
inhibit
cpv
infect
examin
h
incub
use
cell
count
kit
transgen
biotech
beij
china
valu
calcul
via
bestfit
log
dose
respons
curvefit
graphpad
prism
softwar
version
la
jolla
ca
usa
absolut
quantif
pcr
use
evalu
anticpv
effect
total
dna
isol
infect
cell
use
qiaamp
dna
mini
kit
qiagen
hilden
germani
accord
manufactur
instruct
cpv
specif
primer
use
amplifi
fragment
obtain
fragment
clone
takara
shiga
japan
result
posit
clone
name
use
evalu
antivir
effect
three
drug
nitazoxanid
closantel
sodium
closantel
cell
seed
plate
cell
per
well
pretreat
drug
final
concentr
respect
h
treat
cell
infect
cpv
moi
describ
cell
treat
dmso
use
control
h
incub
total
dna
extract
whole
cell
lysat
qiaamp
dna
mini
kit
qiagen
hilden
germani
quantit
standard
curv
gener
via
quantit
realtim
pcr
plasmid
prepar
serial
dilut
qpcr
reaction
mixtur
contain
dilut
sampl
superr
premix
plu
sybr
green
tiangen
biotech
beij
china
specif
primer
mixtur
load
stepon
plu
qpcr
machin
appli
biosystem
usa
qpcr
procedur
min
follow
cycl
absolut
number
dna
copi
gene
cell
determin
accord
gener
standard
curv
immunofluoresc
assay
ifa
use
evalu
antivir
effect
identifi
drug
cell
plate
cellswel
pretreat
predilut
nitazoxanid
closantel
sodium
closantel
final
concentr
respect
h
treat
cell
infect
cpv
moi
h
postinfect
cell
fix
aceton
incub
dilut
mous
monoclon
antibodi
ingenasa
madrid
spain
min
follow
incub
dilut
fluorescein
isothiocyanateconjug
goat
antimous
igg
hl
highli
crossadsorb
secondari
antibodi
invitrogen
carlsbad
ca
usa
final
cell
stain
dapi
order
label
cell
nuclei
focu
wash
cell
examin
high
content
imag
system
operetta
perkinelm
waltham
usa
magnif
time
addit
experi
use
test
drug
inhibit
stage
cpv
replic
life
cycl
meanwhil
inhibitori
effect
identifi
drug
differ
time
point
follow
addit
three
drug
viru
infect
also
evalu
assay
briefli
cell
seed
plate
cellswel
infect
cpv
moi
nitazoxanid
closantel
sodium
closantel
dmso
ad
h
h
preinfect
h
cpv
infect
h
h
h
h
h
postinfect
determin
inhibitori
effect
differ
time
point
drug
addit
cell
treat
dmso
serv
control
effect
drug
inhibit
evalu
use
cell
count
kit
transgen
biotech
beij
china
h
postinfect
describ
western
blot
also
use
evalu
antivir
activ
nitazoxanid
closantel
sodium
closantel
differ
subspeci
cpv
variant
cell
seed
plate
cell
per
well
pretreat
three
drug
final
concentr
respect
h
treat
cell
infect
cpv
variant
new
strain
new
strain
new
strain
moi
describ
cell
dmso
use
control
h
incub
cell
harvest
lyse
mammalian
total
protein
extract
kit
transgen
biotech
china
equal
amount
cell
lysat
analyz
via
sodium
dodecyl
sulphat
polyacrylamid
gel
electrophoresi
sdspage
transfer
onto
polyvinyliden
difluorid
pvdf
membran
millipor
burlington
usa
block
milktbstween
h
room
temperatur
monoclon
antibodi
dilut
ingenasa
madrid
spain
betaactin
monoclon
antibodi
dilut
thermo
scientif
waltham
usa
ad
incub
overnight
blot
incub
horseradishperoxidas
hrp
conjug
goat
antimous
igg
h
immunoreact
band
detect
use
west
pico
plu
chemiluminesc
substrat
kit
thermo
scientif
usa
imag
use
chemiluminesc
apparatu
proteinsimpl
usa
band
intens
measur
use
imag
j
softwar
viral
protein
express
first
compar
beta
actin
express
normal
dmsotreat
group
cell
seed
plate
cellswel
pretreat
nitazoxanid
closantel
sodium
closantel
final
concentr
infect
cpv
moi
cell
incub
h
h
h
h
assay
perform
triplic
caspaseglo
assay
kit
promega
usa
use
detect
pro
antiapoptot
effect
identifi
drug
luminesc
sampl
measur
use
synergi
micropl
reader
biotek
instrument
inc
winooski
usa
accord
manufactur
instruct
drug
determin
bestfit
log
dose
respons
curvefit
graphpad
prism
oneway
analysi
varianc
anova
dunnett
multipl
comparison
test
use
analyz
data
statist
signific
denot
follow
p
p
p
p
studi
cpebas
highthroughput
screen
assay
use
screen
cpv
inhibitor
fdaapprov
drug
librari
timelin
drug
treatment
cpv
infect
well
flow
chart
cpebas
assay
shown
figur
b
primari
screen
first
round
z
factor
across
drug
plate
assay
qualiti
control
index
z
factor
plate
demonstr
cpebas
screen
assay
suitabl
screen
anticpv
drug
mean
percentag
cpe
inhibit
drug
plot
figur
twentyon
drug
cpe
inhibit
identifi
first
round
screen
use
second
round
screen
drug
name
catalogu
number
selleck
final
percentag
cpe
inhibit
drug
list
tabl
inhibitori
effect
drug
drug
ad
h
postviru
infect
also
list
tabl
seven
drug
percentag
cpe
inhibit
select
assay
result
shown
figur
figur
also
list
tabl
top
three
closantel
sodium
identifi
higher
percentag
cpe
inhibit
respect
concentr
tabl
moreov
three
drug
show
dosedepend
inhibit
cpv
infect
figur
absolut
qpcr
result
dosedepend
reduct
copi
number
cpv
viral
dna
observ
increas
concentr
nitazoxanid
figur
closantel
sodium
figur
closantel
figur
cpvinfect
cell
treat
three
drug
cpv
viral
dna
copi
number
whole
cell
lysat
significantli
reduc
nitazoxanid
closantel
sodium
closantel
compar
dmsotreat
group
figur
shown
figur
cpv
infect
could
inhibit
presenc
nitazoxanid
closantel
sodium
closantel
concentr
cell
cpvposit
treat
drug
almost
green
signal
detect
cell
treat
drug
result
confirm
identifi
drug
inhibit
cpv
infect
dosedepend
manner
consist
qpcr
assay
result
consist
screen
result
three
drug
show
anticpv
effect
ad
h
viru
infect
preinfect
inhibitori
effect
nitazoxanid
closantel
sodium
closantel
respect
three
drug
ad
h
postviru
infect
figur
drug
inhibit
earli
process
cpv
replic
cycl
inhibit
effect
rel
high
within
h
postinfect
figur
addit
anticpv
activ
nitazoxanid
observ
drug
ad
h
postinfect
suggest
nitazoxanid
may
partial
abil
inhibit
cpv
infect
stage
viral
replic
western
blot
also
use
evalu
broadspectrum
antivir
activ
identifi
drug
differ
subspeci
three
cpv
variant
dosedepend
reduct
express
quantif
rel
express
level
shown
cell
treat
nitazoxanid
figur
closantel
sodium
figur
e
closantel
figur
f
respect
nitazoxanid
treat
reduc
rel
express
differ
cpv
variant
respect
figur
closantel
sodium
treat
reduc
rel
express
differ
cpv
variant
respect
figur
closantel
treat
reduc
rel
express
differ
cpv
variant
respect
figur
identifi
drug
show
inhibitori
abil
cpv
variant
doley
et
al
report
cpv
could
induc
caspasedepend
involv
extrins
intrins
endoplasm
reticulum
pathway
apoptosi
madindarbi
canin
kidney
mdck
cell
order
evalu
whether
drugassoci
apoptosi
involv
antivir
effect
measur
activ
drugtreat
cell
without
cpv
infect
shown
figur
antiapoptot
effect
observ
within
h
nitazoxanidetr
cell
without
cpv
infect
therefor
nitazoxanideassoci
caspas
activ
reduct
apoptosi
might
involv
antivir
effect
drug
closantel
sodium
closanteltr
cell
pro
antiapoptot
effect
figur
henc
antivir
effect
two
drug
may
due
drugassoci
apoptosi
cpv
wide
distribut
viru
contain
least
three
main
subspeci
current
commerci
vaccin
provid
complet
protect
cpv
variant
moreov
effect
drug
avail
control
cpv
infect
except
support
symptombas
care
henc
import
develop
altern
treatment
cpv
infect
studi
develop
cpebas
assay
screen
cpv
inhibitor
fdaapprov
drug
librari
success
identifi
three
fdaapprov
cpv
inhibitor
drug
might
provid
potenti
treatment
option
anticpv
infect
although
select
index
si
gemcitabin
hcl
cladribin
gemcitabin
trifluridin
higher
level
tabl
percentag
cpe
inhibit
four
drug
alway
maintain
lower
level
figur
maximum
percentag
cpe
inhibit
drug
rel
lower
cpe
inhibit
level
would
increas
increas
drug
concentr
therefor
nitazoxanid
closantel
sodium
closantel
select
studi
mention
identifi
drug
nitazoxanid
closantel
sodium
closantel
reduc
copi
number
cpv
viral
dna
respect
compar
dmsotreat
control
figur
meanwhil
ifa
result
also
show
identifi
drug
inhibit
cpv
infect
dosedepend
reduct
manner
western
blot
show
nitazoxanid
treatment
reduc
rel
express
three
cpv
variant
reduct
rate
follow
closantel
sodium
closantel
treatment
respect
figur
result
indic
identifi
drug
signific
inhibitori
effect
cpv
infect
cell
previou
studi
two
drug
oseltamivir
cidofovir
ad
second
round
screen
neuraminidas
na
inhibitor
oseltamivir
use
treat
human
influenza
viru
savigni
macintir
use
oseltamivir
cpv
enter
found
oseltamivirtr
group
gain
signific
increas
weight
chang
white
blood
cell
wbc
count
compar
control
group
howev
author
also
report
obviou
advantag
establish
cidofovir
broadspectrum
antidna
viru
drug
evalu
treatment
human
papillomaviru
hpv
associ
tumor
cpebas
screen
assay
show
percentag
cpe
inhibit
oseltamivir
cidofovir
tabl
respect
two
drug
anticpv
effect
cell
previous
nitazoxanid
use
treat
cryptosporidiosi
giardiasi
parasit
infect
recent
nitazoxanid
report
inhibit
variou
dna
rna
virus
includ
hepat
b
viru
hbv
human
cytomegaloviru
hcmv
influenza
viru
hepat
c
viru
noroviru
rotaviru
japanes
enceph
viru
jev
coronaviru
chikungunya
viru
chikv
human
immunodefici
viru
hiv
zikv
antivir
mechan
nitazoxanid
remain
unclear
nitazoxanid
could
impair
termin
glycosyl
influenza
hemagglutinin
protein
format
rubella
viru
surfac
glycoprotein
complex
rubella
viru
rv
thu
affect
assembl
influenza
viru
rv
respect
addit
nitazoxanid
could
also
hinder
interact
protein
rotaviru
interact
protein
zikv
dengu
viru
mercorelli
et
al
also
report
nitazoxanid
inhibit
transcript
activ
properti
hcmv
immediateearli
protein
result
indic
virusspecif
effect
nitazoxanid
sinc
nitazoxanid
inhibit
replic
variou
dna
rna
virus
variou
studi
focus
identifi
host
factor
explain
broad
antivir
activ
nitazoxanid
ashiru
et
al
report
nitazoxanid
deplet
intracellular
store
besid
phosphoryl
pkr
affect
nlink
glycosyl
bovin
viral
diarrhea
viru
bvdv
protein
traffick
er
golgi
nitazoxanid
elicit
antivir
innat
immun
reduc
hiv
replic
activ
interferon
system
express
variou
interferonstimul
gene
isg
addit
nitazoxanid
might
block
product
acetylcoa
requir
metabol
intermedi
vaccinia
viru
vacv
reproduct
gener
studi
still
requir
clearli
elucid
antivir
mechan
nitazoxanid
closantel
sodium
closantel
also
identifi
shown
anticpv
activ
closantel
salicylanilid
deriv
consid
anthelmint
agent
livestock
antiangiogenesi
anticanc
effect
closantel
sodium
closantel
also
previous
report
howev
knowledg
neither
antivir
activ
antivir
mechan
closantel
sodium
closantel
report
previou
studi
shown
closantel
inhibit
braf
serinethreonin
kinas
adenin
nucleotid
translocas
ant
spak
kinas
addit
senkowski
et
al
report
closantel
could
inhibit
mitochondri
respir
well
report
may
contribut
studi
antivir
mechan
closantel
studi
aim
identifi
anticpv
drug
potenti
therapeut
use
cpebas
assay
develop
screen
cpv
inhibitor
fdaapprov
drug
librari
screen
top
three
drug
nitazoxanid
closantel
sodium
closantel
higher
percentag
cpe
inhibit
select
confirm
qpcr
ifa
addit
identifi
drug
inhibit
differ
subspeci
cpv
variant
display
broadspectrum
antivir
activ
cpv
henc
drug
may
provid
potenti
option
treatment
cpv
infect
